Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shareholders of Veeva Systems (NYSE: VEEV ) , a cloud company focused on helping drug companies streamline the sales and regulatory processes, saw their stock climb as much as 17% today.
So What: Veeva reported earnings and revenue that came in above expectations, and raised guidance for the full year.
Specifically, Veeva saw revenue climb 53% as non-GAAP income shot 69% higher. Much of that jump was due to the fact the company continued to show strength in its Veeva CRM solutions -- which help integrate medical sales information under one umbrella.
Veeva's other line of business -- Veeva Vault -- focuses on helping life sciences companies streamline clinical trials and the regulatory process. The company added 10 new customers for its signature eTMF service, with one of them being its second top 10 pharma company.
For the rest of the year, the company raised both its earnings and revenue outlooks. Veeva now expects non-GAAP EPS of $0.31 -- up 15% from previous projections -- on revenue of $302 million -- up 8% from its previous forecast.
Now What: Veeva is a newly IPO'd company this year, and it has had a volatile run on the public markets. And given the large number of shares sold short previous to today, some of the stock's movement could be due to a short squeeze.
With shares now trading hands for 100 times trailing earnings, there are high expectations built into the stock. That shouldn't necessarily stop you from buying shares -- I own them myself. If Veeva is able to capture Big Pharma customers with its incredibly sticky product, it could be dominant for decades to come.
But investors need to understand that if the company falls short of these expectations, huge downswings in the stock price will follow. That's why my personal stake is less than 1% of my portfolio right now. I'd suggest a similarly cautious approach.
Leaked: This coming blockbuster will make even Veeva jealous
Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.